Company news

Vertex Pharmaceuticals Incorporated news in 2023

Vertex Pharmaceuticals Incorporated's news releases, calls and decks from 2023, newest first.

View company

Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8

December 17, 2023

Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

December 14, 2023

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

December 12, 2023

Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition

December 10, 2023

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

December 7, 2023

Vertex Appoints Nancy Thornberry to its Board of Directors

December 4, 2023

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

November 29, 2023

Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations

November 23, 2023

European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

November 22, 2023

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

November 15, 2023

Vertex Reports Third Quarter 2023 Financial Results

November 5, 2023

Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition

November 1, 2023

Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference

November 1, 2023

Vertex to Present at Upcoming Investor Conferences

October 25, 2023

Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation

October 17, 2023

Vertex to Announce Third Quarter 2023 Financial Results on November 6

October 9, 2023

Vertex Appoints Michel Lagarde to its Board of Directors

October 4, 2023

Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting

October 2, 2023

Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5

September 14, 2023

Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences

September 13, 2023

Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13

August 29, 2023

Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

August 28, 2023

Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

August 2, 2023

Vertex Reports Second Quarter 2023 Financial Results

July 31, 2023

European Commission Approves ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children With Cystic Fibrosis Ages 1 to <2 Years Old

July 4, 2023

Vertex to Announce Second Quarter 2023 Financial Results on August 1

June 29, 2023

Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies

June 25, 2023

Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

June 22, 2023

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

June 8, 2023

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

June 8, 2023

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

June 7, 2023

Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13

May 29, 2023

Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older

May 2, 2023

Vertex Reports First Quarter 2023 Financial Results

April 30, 2023

Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations

April 25, 2023

Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9

April 24, 2023

Vertex Announces Health Canada Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 Years

April 10, 2023

Vertex to Announce First Quarter 2023 Financial Results on May 1

April 9, 2023

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

April 2, 2023

Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

March 26, 2023

Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)

March 15, 2023

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes

March 8, 2023

Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7

February 20, 2023

Vertex Reports Fourth Quarter and Full Year Financial 2022 Results

February 6, 2023

Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7

January 16, 2023

Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9

January 3, 2023

Calls in 2023

Decks in 2023